Iris Zemzoum, Novartis Pharma's president for Asia Pacific, Middle East and Africa, outlines how the company is shaping its strategy in the region, which comes with “extremes” in market profiles, via a distinct archetype that factors in commonalities between national healthcare systems. The company is also progressing interesting initiatives in digital therapeutics.

One year on, we’ve seen how the coronavirus prompted entrepreneurial instincts to surface in the medtech and healthtech sectors. Asia healthtech investor specialist HealthXCapital tells Medtech Insight about the changes that are likely to stick as in an industry that has seen the value of rapid responsiveness to acute need.

Asia continues to gain attention for its healthtech innovation and adoption activity, and VC investors have seen the merits of a maintaining a focus on this newly emerging regional innovation hotspot, regardless of the pandemic.

Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.